Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 2
2004 5
2005 4
2006 5
2007 2
2008 2
2009 1
2010 3
2011 7
2012 8
2013 5
2014 6
2015 7
2016 7
2017 2
2018 4
2019 1
2020 4
2021 10
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk D, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields AF, Cheung NV, Lum LG. Yankelevich M, et al. Among authors: lum lg. J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744. J Immunother Cancer. 2024. PMID: 38519053 Free PMC article. Clinical Trial.
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Fadul CE, Thakur A, Kim J, Kassay-McAllister J, Schalk D, Lopes MB, Donahue J, Purow B, Dillon P, Le T, Schiff D, Liu Q, Lum LG. Fadul CE, et al. Among authors: lum lg. J Neurooncol. 2024 Jan;166(2):321-330. doi: 10.1007/s11060-024-04564-y. Epub 2024 Jan 23. J Neurooncol. 2024. PMID: 38263486 Free PMC article. Clinical Trial.
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. Yankelevich M, et al. Among authors: lum lg. Res Sq [Preprint]. 2023 Nov 9:rs.3.rs-3570311. doi: 10.21203/rs.3.rs-3570311/v1. Res Sq. 2023. PMID: 37986911 Free PMC article. Updated. Preprint.
Disparate Regions of the Human Chemokine CXCL10 Exhibit Broad-Spectrum Antimicrobial Activity against Biodefense and Antibiotic-Resistant Bacterial Pathogens.
Crawford MA, Ward AE, Gray V, Bailer P, Fisher DJ, Kubicka E, Cui Z, Luo Q, Gray MC, Criss AK, Lum LG, Tamm LK, Letteri RA, Hughes MA. Crawford MA, et al. Among authors: lum lg. ACS Infect Dis. 2023 Jan 13;9(1):122-139. doi: 10.1021/acsinfecdis.2c00456. Epub 2022 Dec 7. ACS Infect Dis. 2023. PMID: 36475632 Free PMC article.
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Vaishampayan UN, Thakur A, Chen W, Deol A, Patel M, Dobson K, Dickow B, Schalk D, Schienschang A, Whitaker S, Polend A, Fontana JA, Heath EI, Lum LG. Vaishampayan UN, et al. Among authors: lum lg. Clin Cancer Res. 2023 Jan 4;29(1):122-133. doi: 10.1158/1078-0432.CCR-22-1601. Clin Cancer Res. 2023. PMID: 36255393 Free PMC article. Clinical Trial.
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile.
Sturek JM, Thomas TA, Gorham JD, Sheppard CA, Raymond AH, Petros De Guex K, Harrington WB, Barros AJ, Madden GR, Alkabab YM, Lu DY, Liu Q, Poulter MD, Mathers AJ, Thakur A, Schalk DL, Kubicka EM, Lum LG, Heysell SK. Sturek JM, et al. Among authors: lum lg. Microbiol Spectr. 2022 Feb 23;10(1):e0256021. doi: 10.1128/spectrum.02560-21. Epub 2022 Feb 23. Microbiol Spectr. 2022. PMID: 35196802 Free PMC article. Clinical Trial.
87 results